Sanofi Ventures has secured an additional $625 million, pushing total assets past $1.4 billion to invest in breakthrough biotech startups. The funding targets innovative therapies across autoimmune, neurological, and oncology domains. This capital influx underscores big pharma’s commitment to early-stage innovation and strategic backing of novel therapeutic platforms poised to reshape future healthcare landscapes.